IN8bio Past Earnings Performance
Past criteria checks 0/6
IN8bio's earnings have been declining at an average annual rate of -39.7%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-39.7%
Earnings growth rate
31.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -120.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate
Apr 03
Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky
Nov 04Is IN8bio (NASDAQ:INAB) In A Good Position To Invest In Growth?
Jan 26Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation
Oct 12IN8bio gains 53% as H.C. Wainwright initiates with Buy
Aug 30IN8bio raises additional funds from underwriter of stock offering
Aug 19IN8bio prices $10.25M stock offering
Aug 12We're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Rate
Jun 04IN8bio (NASDAQ:INAB) Is In A Good Position To Deliver On Growth Plans
Feb 13IPO Update: IN8bio Aims For Downsized IPO
Jul 29Revenue & Expenses BreakdownBeta
How IN8bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -30 | 14 | 17 |
| 30 Sep 23 | 0 | -30 | 14 | 16 |
| 30 Jun 23 | 0 | -30 | 14 | 17 |
| 31 Mar 23 | 0 | -30 | 14 | 16 |
| 31 Dec 22 | 0 | -29 | 14 | 14 |
| 30 Sep 22 | 0 | -27 | 14 | 13 |
| 30 Jun 22 | 0 | -23 | 13 | 10 |
| 31 Mar 22 | 0 | -18 | 10 | 8 |
| 31 Dec 21 | 0 | -15 | 7 | 7 |
| 30 Sep 21 | 0 | -12 | 5 | 6 |
| 30 Jun 21 | 0 | -11 | 4 | 6 |
| 31 Mar 21 | 0 | -11 | 4 | 6 |
| 31 Dec 20 | 0 | -10 | 3 | 5 |
| 30 Sep 20 | 0 | -9 | 3 | 5 |
| 30 Jun 20 | 0 | -8 | 3 | 4 |
| 31 Mar 20 | 0 | -6 | 3 | 3 |
| 31 Dec 19 | 0 | -6 | 3 | 2 |
Quality Earnings: INAB is currently unprofitable.
Growing Profit Margin: INAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INAB is unprofitable, and losses have increased over the past 5 years at a rate of 39.7% per year.
Accelerating Growth: Unable to compare INAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: INAB has a negative Return on Equity (-120.33%), as it is currently unprofitable.